Literature DB >> 29923209

Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score.

Brian T Helfand1, Haitao Chen2, Richard J Fantus3, Carly A Conran1, Charles B Brendler1, Siquan Lilly Zheng1, Patrick C Walsh4, William B Isaacs4, Jianfeng Xu1.   

Abstract

PURPOSE: Family history assigns equivalent risk to all relatives based upon the degree of relationship. Recent genetic studies have identified single nucleotide polymorphisms (SNPs) that can be used to calculate a genetic risk score (GRS) to determine prostate cancer (PCa) risk. We sought to determine whether GRS can stratify PCa risk among individuals in families considered to be at higher risk due their family history of PCa.
MATERIALS AND METHODS: Family members with hereditary PCa were recruited and genotyped for 17 SNPs associated with PCa. A GRS was calculated for all subjects. Analyses compared the distribution of GRS values among affected and unaffected family members of varying relationship degrees.
RESULTS: Data was available for 789 family members of probands including 552 affected and 237 unaffected relatives. Median GRSs were higher among first-degree relatives compared to second- and third-degree relatives. In addition, GRS values among affected first- and second-degree relatives were significantly higher than unaffected relatives (P = 0.042 and P = 0.016, respectively). Multivariate analysis including GRS and degree of relationship demonstrated that GRS was a significant and independent predictor of PCa (OR 1.52, 95%CI 1.15-2.01).
CONCLUSION: GRS is an easy-to-interpret, objective measure that can be used to assess differences in PCa risk among family members of affected men. GRS allows for further differentiation among family members, providing better risk assessment. While prospective validation studies are required, this information can help guide relatives in regards to the time of initiation and frequency of PCa screening.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  cancer screening; family history; genetic risk score; prostate cancer

Year:  2018        PMID: 29923209      PMCID: PMC6773522          DOI: 10.1002/pros.23664

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  33 in total

1.  Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis.

Authors:  Deborah Watkins Bruner; Dirk Moore; Alicia Parlanti; Joanne Dorgan; Paul Engstrom
Journal:  Int J Cancer       Date:  2003-12-10       Impact factor: 7.396

2.  Polygenes, risk prediction, and targeted prevention of breast cancer.

Authors:  Paul D P Pharoah; Antonis C Antoniou; Douglas F Easton; Bruce A J Ponder
Journal:  N Engl J Med       Date:  2008-06-26       Impact factor: 91.245

3.  Early detection of prostate cancer: AUA Guideline.

Authors:  H Ballentine Carter; Peter C Albertsen; Michael J Barry; Ruth Etzioni; Stephen J Freedland; Kirsten Lynn Greene; Lars Holmberg; Philip Kantoff; Badrinath R Konety; Mohammad Hassan Murad; David F Penson; Anthony L Zietman
Journal:  J Urol       Date:  2013-05-06       Impact factor: 7.450

Review 4.  The influence of family history on prostate cancer risk: implications for clinical management.

Authors:  Stephan Madersbacher; Antonio Alcaraz; Mark Emberton; Peter Hammerer; Anton Ponholzer; Fritz H Schröder; Andrea Tubaro
Journal:  BJU Int       Date:  2010-12-16       Impact factor: 5.588

5.  Family history facilitates the early diagnosis of prostate carcinoma.

Authors:  P C Walsh; A W Partin
Journal:  Cancer       Date:  1997-11-01       Impact factor: 6.860

6.  Genetic predisposition to prostate cancer.

Authors:  R A Eeles
Journal:  Prostate Cancer Prostatic Dis       Date:  1999-01       Impact factor: 5.554

7.  Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines.

Authors:  Peter R Carroll; J Kellogg Parsons; Gerald Andriole; Robert R Bahnson; Daniel A Barocas; William J Catalona; Douglas M Dahl; John W Davis; Jonathan I Epstein; Ruth B Etzioni; Veda N Giri; George P Hemstreet; Mark H Kawachi; Paul H Lange; Kevin R Loughlin; William Lowrance; Paul Maroni; James Mohler; Todd M Morgan; Robert B Nadler; Michael Poch; Chuck Scales; Terrence M Shanefelt; Andrew J Vickers; Robert Wake; Dorothy A Shead; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2014-09       Impact factor: 11.908

8.  Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci.

Authors:  Ali Amin Al Olama; Sara Benlloch; Antonis C Antoniou; Graham G Giles; Gianluca Severi; David E Neal; Freddie C Hamdy; Jenny L Donovan; Kenneth Muir; Johanna Schleutker; Brian E Henderson; Christopher A Haiman; Fredrick R Schumacher; Nora Pashayan; Paul D P Pharoah; Elaine A Ostrander; Janet L Stanford; Jyotsna Batra; Judith A Clements; Suzanne K Chambers; Maren Weischer; Børge G Nordestgaard; Sue A Ingles; Karina D Sorensen; Torben F Orntoft; Jong Y Park; Cezary Cybulski; Christiane Maier; Thilo Doerk; Joanne L Dickinson; Lisa Cannon-Albright; Hermann Brenner; Timothy R Rebbeck; Charnita Zeigler-Johnson; Tomonori Habuchi; Stephen N Thibodeau; Kathleen A Cooney; Pierre O Chappuis; Pierre Hutter; Radka P Kaneva; William D Foulkes; Maurice P Zeegers; Yong-Jie Lu; Hong-Wei Zhang; Robert Stephenson; Angela Cox; Melissa C Southey; Amanda B Spurdle; Liesel FitzGerald; Daniel Leongamornlert; Edward Saunders; Malgorzata Tymrakiewicz; Michelle Guy; Tokhir Dadaev; Sarah J Little; Koveela Govindasami; Emma Sawyer; Rosemary Wilkinson; Kathleen Herkommer; John L Hopper; Aritaya Lophatonanon; Antje E Rinckleb; Zsofia Kote-Jarai; Rosalind A Eeles; Douglas F Easton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-04-02       Impact factor: 4.254

9.  Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial.

Authors:  A Karim Kader; Jielin Sun; Brian H Reck; Paul J Newcombe; Seong-Tae Kim; Fang-Chi Hsu; Ralph B D'Agostino; Sha Tao; Zheng Zhang; Aubrey R Turner; Greg T Platek; Colin F Spraggs; John C Whittaker; Brian R Lane; William B Isaacs; Deborah A Meyers; Eugene R Bleecker; Frank M Torti; Jeffery M Trent; John D McConnell; S Lilly Zheng; Lynn D Condreay; Roger S Rittmaster; Jianfeng Xu
Journal:  Eur Urol       Date:  2012-05-12       Impact factor: 20.096

10.  Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.

Authors:  Ali Amin Al Olama; Tokhir Dadaev; Dennis J Hazelett; Qiuyan Li; Daniel Leongamornlert; Edward J Saunders; Sarah Stephens; Clara Cieza-Borrella; Ian Whitmore; Sara Benlloch Garcia; Graham G Giles; Melissa C Southey; Liesel Fitzgerald; Henrik Gronberg; Fredrik Wiklund; Markus Aly; Brian E Henderson; Fredrick Schumacher; Christopher A Haiman; Johanna Schleutker; Tiina Wahlfors; Teuvo L Tammela; Børge G Nordestgaard; Tim J Key; Ruth C Travis; David E Neal; Jenny L Donovan; Freddie C Hamdy; Paul Pharoah; Nora Pashayan; Kay-Tee Khaw; Janet L Stanford; Stephen N Thibodeau; Shannon K Mcdonnell; Daniel J Schaid; Christiane Maier; Walther Vogel; Manuel Luedeke; Kathleen Herkommer; Adam S Kibel; Cezary Cybulski; Dominika Wokołorczyk; Wojciech Kluzniak; Lisa Cannon-Albright; Hermann Brenner; Katja Butterbach; Volker Arndt; Jong Y Park; Thomas Sellers; Hui-Yi Lin; Chavdar Slavov; Radka Kaneva; Vanio Mitev; Jyotsna Batra; Judith A Clements; Amanda Spurdle; Manuel R Teixeira; Paula Paulo; Sofia Maia; Hardev Pandha; Agnieszka Michael; Andrzej Kierzek; Koveela Govindasami; Michelle Guy; Artitaya Lophatonanon; Kenneth Muir; Ana Viñuela; Andrew A Brown; Mathew Freedman; David V Conti; Douglas Easton; Gerhard A Coetzee; Rosalind A Eeles; Zsofia Kote-Jarai
Journal:  Hum Mol Genet       Date:  2015-05-29       Impact factor: 6.150

View more
  1 in total

1.  Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.

Authors:  Jennifer L Beebe-Dimmer; Ashley L Kapron; Alison M Fraser; Ken R Smith; Kathleen A Cooney
Journal:  J Clin Oncol       Date:  2020-03-24       Impact factor: 44.544

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.